FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Fibromyalgia

Therapeutic area intelligence for Fibromyalgia with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Pilot →

Recent signals(3)

ClinicalAugust 10, 2026

Trial on tDCS Efficacy in Fibromyalgia Underway

A randomized controlled trial (NCT07583056) is currently underway to evaluate the non-inferiority and potential superiority of a high-dose home-based transcranial direct current stimulation (tDCS) protocol compared to a conventional home-based protocol in patients with fibromyalgia.

ClinicalJuly 27, 2026

Study on Interdisciplinary Program to Enhance Quality of Life in Fibromyalgia Patients

A quasi-experimental study is evaluating the effectiveness of a multidisciplinary program for fibromyalgia patients in Spain.

Clinical

June 27, 2026

Pilot Study on Osteopathic Intervention for Fibromyalgia Patients Initiated

A pilot study evaluating the efficacy of osteopathic care for fibromyalgia patients has been initiated with 44 participants.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.